Protein Sciences Corporation announced that FDA has extended the shelf life for Flublok, its game changing seasonal influenza vaccine, to 9 months from the date of manufacture- increasing the previous shelf life by 3 months.
The longer shelf life will make it easier for healthcare providers and pharmacies to stock Flublok and vaccinate people throughout the influenza season, which in some years can last as long as April or May.
“We are pleased to add an extended shelf life to the list of product improvements we have been able to achieve for Flublok,” said Dr. Penny Post, Protein Sciences Vice President, Regulatory Affairs. “We were first able to expand the approved age range for Flublok to everyone 18 years and older in October 2014. In addition to the 9 month shelf life we just achieved, Flublok Quadrivalent is under review and FDA approval is anticipated this fall. We are working towards securing a one year shelf life as well.”
In addition to Flublok’s undeniable purity due to the absence of many ingredients that make traditional flu vaccines objectionable to some like mercury, antibiotics, or formalin, Flublok is highly effective. In a clinical study of approximately 9,000 adults 50 years and older, Flublok proved to be 43 percent more effective than a traditional egg-based flu vaccine in protecting people against cell culture confirmed influenza. Therefore, Flublok is a high efficacy vaccine for the entire adult population.
For more information about Flublok, visit www.flublok.com.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
